862974-25-2

In a murine model, the half-life of N106 is determined to be ～65.4?min with a C_max of ～2.24?μM when the mice received 10?mg/kg of N106 by intravenous injection. The oral bioavailability (F%) is 56% and 50%, and terminal elimination half-life (t_1/2) is 19?min^[1].
? In vivo, N106 (10 mg/kg) increases cardiac SERCA2A SUMOylation, and significantly improves ventricular function in mice with heart failure^[1].